1. Introduction {#s0005}
===============

Osteoporosis is a silent and progressive systemic skeletal disorder resulting in low bone mineral density (BMD) with fracture as its associated clinical consequence ([@bb0030]). The maintenance of skeletal strength through bone remodeling is regulated through complex interactions between bone cells and endocrine cells ([@bb0120]). There is evidence for the role of gastro-intestinal hormones secreted in response to food intake in the maintenance of skeletal integrity and altered profiles of bone turnover-markers have been observed in the aftermath of meal ingestion ([@bb0040], [@bb0075]). Glucose-dependent insulinotropic polypeptide (also known as gastric inhibitory polypeptide (GIP)) is one such gastro-intestinal hormone. Secreted by K cells in the small intestine, GIP potentiates glucose-induced insulin secretion from pancreatic β-cells leading to reduced blood glucose levels ([@bb0125]). *In vitro* studies have shown that GIP inhibits osteoclast differentiation and activity via a direct mechanism which may lead to a net effect of increased bone mass, although the effects of GIP could also be mediated, at least in part, by variation in insulin secretion ([@bb0045]); in rats, administration of GIP reduces bone loss after ovariectomy ([@bb0015], [@bb0010], [@bb0155]).

GIP receptor (GIPR) is expressed in osteoblasts, osteocytes and osteoclasts as well as a wide range of tissues including adipocytes, pancreas, lungs, kidney and thyroid ([@bb0010], [@bb0155]). Studies of transgenic mice overexpressing *GIP* show higher BMD and bone mineral content (BMC) than controls while in addition, they have elevated serum levels of GIP and total osteocalcin ([@bb0035]). Furthermore, in these mice, an age dependent decrease in *GIPR* expression has also been observed. Conversely, knockout mice deficient in *GIPR* have deranged cortical microarchitecture of bone leading to reduced bone 'quality' and strength and low fat mass ([@bb0105]). Taken together these observations represent one aspect of the complex shared molecular mechanisms between osteoporosis and diabetes. Type 1 diabetes (T1D) is associated with low BMD and increased fracture risk ([@bb0145]) while type 2 diabetes (T2D), with its increased risk of fracture despite normal bone mass ([@bb0080], [@bb0110]), is complicated by the complex relationship between body weight, osteoporosis and T2D.

In a meta-analysis of genome-wide association studies, a variant (rs10423928) in the *GIPR* gene has been found to be associated with elevated postprandial glucose and insulin ([@bb0125]) as well as lean body composition including decreased BMI, lean mass and waist circumference ([@bb0095]), hence its selection for this study. Only one study however has investigated *GIPR* variation in relation to BMD; reporting that a functional SNP in linkage disequilibrium with rs10423928 was associated with low BMD in early postmenopausal women ([@bb0135]). To date there have been no population-based studies investigating association of variants in the *GIP* gene with bone phenotypes.

The primary aim of our study was to investigate the association of SNPs in the *GIP* and *GIPR* genes with skeletal phenotypes beyond bone density (BMC, bone microarchitecture, fracture), body composition and serum GIP level. Since menopausal (estrogen) status may influence the association, the study was performed in two population-based cohorts consisting of 75 year and 25 year old women.

2. Materials and methods {#s0010}
========================

2.1. Subjects {#s0015}
-------------

Two population based cohorts of Swedish women living in Malmö, Sweden were studied; the Osteoporosis Prospective Risk Assessment cohort (OPRA) consisting of 1044 elderly women aged 75 at inclusion and followed-up at 5 years (n = 715) and 10 years (n = 382) and the PEAK-25 cohort consisting of 1061 women all 25 years old at inclusion. Details of the cohorts have been published elsewhere ([@bb0065], [@bb0100]). All study participants gave written informed consent and the study was approved by the Regional Ethical Review Board in Lund, Sweden.

2.2. DXA --- bone phenotypes and body composition {#s0020}
-------------------------------------------------

BMD was measured for total body (TB), femoral neck (FN), and lumbar spine (LS) using dual-energy X-ray absorptiometry (DXA) (Lunar Prodigy: PEAK-25; Lunar DPX-L: OPRA (Lunar Corporation, Madison, WI, USA). Total body fat mass (FM) and lean mass (LM) were also measured by using DXA. All measurements were performed using the same instrument. At baseline, software versions 1.33 and 1.35 (OPRA) and 2.05, 2.15, 3.60, 5.70 and 7.70 (PEAK-25) were used. Version 4.7e was used for OPRA 10 year follow-up. Calibrations were performed daily using a manufacturer supplied phantom. Precision (coefficient of variation (CV)) for DXA scanning was 0.94% (TB), 1.45% (LS) and 4.01% (FN) in the OPRA cohort ([@bb0090]) and 0.90% (FN) and 0.65% (LS) in PEAK-25 ([@bb0020]).

2.3. Bone microarchitecture at the spine and heel {#s0025}
-------------------------------------------------

We also assessed aspects of bone strength as reflected by microarchitecture (or bone 'quality') measured by quantitative ultrasound (QUS): speed of sound (SoS) (m/s), broadband ultrasound attenuation (BUA) (dB/MHz), and stiffness index (SI). Measurements were performed using the Lunar Achilles (R) system (Lunar Corporation Madison, WI, USA) in both cohorts. The CV was 1.5% for derivatives of BUA and SoS ([@bb0085]). Daily calibrations were performed.

Microarchitecture in the spine was measured using the trabecular bone score (TBS), a novel approach applied to the DXA image. Due to technical limitations TBS could not be calculated from the Lunar DPX-L, therefore spine acquisitions were available only for the PEAK-25 cohort. Posteroanterior spine acquisitions were analyzed using the manufacture\'s software (Encore 2004; GE Medical-Lunar, Madison, WI) and a standardized protocol ([@bb0070]). TBS was calculated as the mean value of the individual measurements for each vertebra (L1 to L4).

2.4. Incident fracture {#s0030}
----------------------

In the OPRA cohort information on incident fractures was obtained through questionnaires at 1, 3, 5 and 10 years after the baseline investigation. These fractures and all fractures occurring until October 2012 providing a maximum follow-up for fracture of 17.2 years (mean 13.1 years) were verified in files at the Department of Radiology, Skåne University Hospital, Malmö, Sweden. We focused on analyzing "Any Incident Fracture" as a single category. This category included hip, distal radius, vertebra, shoulder, pelvis and proximal tibia fractures. Fractures of the face, hands and feet were excluded. The majority of fractures (\> 99%) were attributed to low energy trauma. In the PEAK-25 cohort, fracture incidence was not analyzed due to the low numbers of fractures occurring at this age.

2.5. Serum GIP {#s0035}
--------------

Serum GIP (s-GIP measurements were available only in the OPRA cohort; at 10 year follow-up. Levels of s-GIP were successfully measured for n = 363/382 participants. s-GIP was measured in fasting samples using a human GIP (Total) ELISA kit (Millipore, R&D Systems, Abingdon, UK) ([@bb0005]). The assay was performed following the manufacturer\'s instructions. No samples fell below the lower limit of detection (8.2 pg/ml). The inter-assay CV was 2--6% while CV for the study samples was 4.3--5.6.

2.6. Genotyping {#s0040}
---------------

Total genomic DNA was isolated from blood using the QIAamp 96 DNA blood kit (Qiagen, Valencia, CA, USA) according to the manufacturer\'s instructions. In this study, we analyzed rs2291725 (G/A, S103G) located in exon 4 of *GIP* and rs10423928 (T/A) in intron 12 of GIPR ([Table 1](#t0005){ref-type="table"}). The *GIP* SNP rs2291725 was chosen since it is a high frequency missense variation in the *GIP* gene changing amino acid number 103 in the GIP protein (Ser to Gly). The rationale for selection of the *GIPR* SNP lies in the fact that in a combined analysis of several GWAS studies the risk genotype of rs10423928 showed impaired insulin secretion. This *GIPR* SNP is in strong linkage disequilibrium (r2 = 0.99) with the non-synonymous SNP rs1800437 (E354Q) analyzed in the study by [@bb0135]. Consequently the two SNPs reflect the same genetic variation in the gene.

From those who agreed to provide whole blood for DNA analyses, a total of 990 women from OPRA and 992 women from PEAK-25 were genotyped successfully using TaqMan (ABI, Foster City, USA). Approximately 3% of the samples from each cohort were genotyped in duplicate with 100% concordance. Both polymorphisms conformed to Hardy--Weinberg equilibrium and the minor allele frequencies did not differ from other European populations. Genotype and allele frequencies did not differ between cohorts.

2.7. Statistical analyses {#s0045}
-------------------------

All statistical analyses were performed using SPSS version 22 (IBM Corp., NY, USA). To analyze association between genotypes and fracture, the χ^2^ test was used. Logistic regression analysis with adjustment for fat mass and smoking were also used. Unadjusted analyses for continuous variables (BMD, BMC, ultrasound, trabecular bone score and body composition) were performed using the Kruskal-Wallis to test for all three genotypes. Genotype association with continuous variables was also performed using regression analysis. Multivariate regression analysis was used to identify confounding factors. Therefore bone phenotypes were adjusted for fat mass (trabecular bone score was additionally adjusted for lumbar spine BMD) and body composition phenotypes adjusted for smoking. The results were not appreciable different when corrected for diabetes, therefore in the presented results women who reported having diabetes (either type I or type II; n = 69) were not excluded from the analyses. A priori power analyses, assuming a SD of 0.13 g/cm^2^ in BMD, indicated that our sample size allowed \> 80% power to detect differences of 0.065 g/cm^2^ between genotypes assuming a minor allele frequency of \> 0.21. Nominal significance was considered with associations of p \< 0.05. We report the uncorrected p-values, acknowledging that multiple tests were performed.

3. Results {#s0050}
==========

The characteristics of the women from the two differently aged cohorts have been published previously ([@bb0065], [@bb0100]). Briefly, elderly women from the OPRA cohort, as expected, had higher BMI and fat mass and lower lean mass and bone mineral density than the young women from PEAK-25 cohort (Supplementary Table 1). Both fat and lean mass were strongly positively associated with BMD and QUS ([@bb0020], [@bb0050], [@bb0060]).

Mean serum GIP level in the OPRA cohort at 10 year follow-up was 58.5 pg/ml \[SD 33.8\]. There was no association between GIP level and any of the bone phenotypes measured at 10 y follow-up, although femoral neck BMD and BMC were lower in the highest GIP tertile compared to the lowest (BMD: 0.693 vs 0.684, p = 0.87; BMC: 3.564 vs 3.517, p = 0.94). Similarly, body composition phenotypes were not associated with serum GIP despite fat and lean mass showing a tendency towards being higher in the highest GIP tertile (TB-fat: 24.2 vs 25.4, p = 0. 57; TB-lean: 35.7 vs 36.1, p = 0.39).

The *GIP* polymorphism was not associated with serum GIP. However, as previously reported ([@bb0095]), the variant 'A' allele of the *GIPR* polymorphism was associated with lower serum GIP in a dose dependent fashion (TT: 54.8 vs TA: 46.1 vs AA: 41.9; p = 0.019) even after adjustment for fat mass (β = − 6.93 (SE 3.19); p~adj~ = 0.03).

In the elderly women, *GIP* genotype was associated with lower BMD at the femoral neck (p~adj~ = 0.016), BMC at total body (p~adj~ = 0.020) and femoral neck (p~adj~ = 0.030), as well as lower QUS_SoS values (p~adj~ = 0.021) at baseline ([Table 2](#t0010){ref-type="table"}) and at 10 year follow-up (data not shown). Conversely, in the young women neither BMD nor BMC were associated with this SNP. Neither did bone properties reflecting microarchitecture (i.e. QUS at the calcaneus and TBS at the spine), differ between genotypes ([Table 2](#t0010){ref-type="table"}).

Variation in *GIPR* was not associated with BMD or BMC in either cohort ([Table 3](#t0015){ref-type="table"}). In PEAK-25, although trabecular bone score did not differ with genotype, women carrying the minor allele had lower calcaneus QUS values, but only BUA and SI reached nominal significance and remained after adjustment for fat mass (BUA β = − 1.63 (SE 0.59), p~adj~ = 0.006; SI β = − 1.86 (SE 0.83), p~adj~ = 0.026). The results remained similar after further adjustment for femoral neck BMD. Conversely, although non-significant, the trend was towards higher QUS values in the elderly women ([Table 3](#t0015){ref-type="table"}).

In PEAK-25, a general trend for association between weight, BMI, fat and lean mass was observed with the *GIP* polymorphism ([Table 2](#t0010){ref-type="table"}). Nominal significance was reached for weight and total body fat mass after adjustment for smoking (p~adj~ = 0.031 and 0.026) ([Table 2](#t0010){ref-type="table"}). There was no association with body composition in OPRA. Variation in *GIPR* was not associated with body composition in either cohort.

Neither *GIP* nor *GIPR* SNPs were associated with occurrence of fractures in the OPRA cohort ([Table 4](#t0020){ref-type="table"}).

4. Discussion {#s0055}
=============

The basis for this study lies in the role of glucose-insulinotropic peptide (GIP) hormone in the regulation of insulin secretion as well as its anabolic effect on osteoblasts and inhibition of osteoclasts ([@bb0140], [@bb0150]). Transgenic mice over-expressing *GIP* have increased cortical bone mass while GIP also appears to prevent age related decline in bone mass and bone strength ([@bb0035]). Thus *GIP* and the receptor to GIP (*GIPR*) genes are attractive biological candidates to understand the genetic relationship between type 2 diabetes and osteoporosis. In this study, comprising two differently aged cohorts of women, we investigated if genetic variants in *GIP* and *GIPR* displayed association with phenotypes contributing to bone phenotypes including bone quantity and structure.

In the present study, BMD and BMC were not associated with *GIPR*; however there was an association, although only in the young women, with lower calcaneal ultrasound values and this was independent of bone density. The absence of an association with bone architecture in the spine however is in line with data from a knock-out mouse model demonstrating that the effects of *GIPR* deficiency on bone microarchitecture ([@bb0105]) differ between predominantly cortical and trabecular skeletal sites ([@bb0055]).

In the recent study from Denmark, a *GIPR* SNP (*rs1800437*), in strong linkage disequilibrium with the rs10423928 SNP used here, was analyzed. They observed an association with lower BMD and increased fracture risk which is in contrast with our findings. Since one would expect Swedish and Danish to be genetically similar, a possible explanation for this divergent finding is that the Danish women were perimenopausal suggesting that *GIPR* has a more important role in the immediate period around estrogen withdrawal rather than during bone accrual or in the very elderly. *GIPR* expression is reduced with age ([@bb0035]) which would appear to support this.

In our study, *GIPR* had an effect on body composition showing small reductions in weight and fat mass. This is largely in line with the findings of [@bb0095], who also demonstrated that the BMI-lowering effect of this SNP neutralized the concomitant association with impaired glucose concentration and GIP-stimulated insulin secretion.

Why the *GIPR* rather than the *GIP* SNP was associated with serum levels of GIP is unclear although decreased receptor activity has been reported for the *GIPR* E354Q (rs1800437) variant ([@bb0055]) which could influence the cycles of receptor desensitization/resensitization. In cultured adipocytes, the receptor has been shown to be down regulated by GIP stimulation and desensitized to further GIP stimulation for a prolonged period ([@bb0115]).

Serum GIP levels are reported to be increased in postmenopausal women ([@bb0115]) and modulated by estrogen replacement therapy ([@bb0130]), in our study however, GIP does not appear to be exerting a bone anabolic effect, at least in this elderly age group. Whether age related differences in sGIP explain our observed results is uncertain.

The *GIP* SNP rs2291725 (Gly103Ser) is a functional variant previously reported to be associated with type 2 diabetes ([@bb0025]) but not yet explored in relation to altered bone phenotypes. In this study, the *GIP* polymorphism was adversely associated with components of bone strength including density, mineral content and microarchitecture in the elderly but not the young women, even after adjustment for fat mass. The absence of an association with body composition directly contrasts with the positive association observed specifically with weight and fat mass in the young PEAK-25 cohort.

The strengths of this study include being the first, to our knowledge, evaluating the importance of *GIP* polymorphisms in relation to bone phenotypes in human cohorts, although a receptor gene polymorphism has been reported once before. In addition, we have not only evaluated BMD but also bone strength and related phenotypes. In the elderly women, we also analyzed serum GIP, although a weakness of the investigation is that this was only available for only 363 individuals, hence the statistical power to detect association was limited. In addition, serum levels could not be determined in the young making it difficult to establish potential interaction between serum GIP levels, bone properties, body composition and genotype at different ages. A limitation of the study is the fact that neither of the SNPs has been identified as major candidate genes in GWAS for osteoporosis related phenotypes. However, since SNP based GWAS do not identify all disease risk variants, studies of variants identified in related pathways are still warranted. We also acknowledge that the results must be interpreted with caution, since the associations are modest, in the absence of stringent adjustment for multiple testing.

Underlying this study is the hypothesized importance of insulin and glucose metabolism on bone. In our investigation of *GIP* and *GIPR* gene polymorphisms in relation to bone phenotypes in young and old women our findings depict a complex relationship between glucose metabolism genes and bone. In the current setting, it is not possible to explore the reason for these observations. Further studies in equivalent populations are merited to explore these associations further.

The following is the supplementary data related to this article.Supplementary Table 1Cohort baseline details.
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###### 

Genotype and allele frequencies of the polymorphisms studied.

  SNP_Gene     OPRA      MAF       PEAK-25   MAF                                  
  ------------ --------- --------- --------- ------ --------- --------- --------- ------
  rs10423928   610       335       45        0.21   606       324       60        0.22
  *GIPR*       (61.6%)   (33.8%)   (4.6%)           (61.2%)   (32.7%)   (6.1%)    
                                                                                  
               GG        GA        AA               GG        GA        AA        
  rs2291725    271       493       226       0.47   260       507       225       0.48
  *GIP*        (27.4%)   (49.8%)   (22.8%)          (26.2%)   (51.1%)   (22.7%)   

GIP --- gastric inhibitory polypeptide; GIPR --- gastric inhibitory polypeptide receptor.

###### 

Association of *GIP* rs2291725 with bone phenotypes and body composition.

  OPRA                                                     GG                     GA                     AA                     β-Value (adj)[a](#tf0005){ref-type="table-fn"}   p[b](#tf0010){ref-type="table-fn"}   p[c](#tf0015){ref-type="table-fn"} (adj)
  -------------------------------------------------------- ---------------------- ---------------------- ---------------------- ------------------------------------------------ ------------------------------------ ------------------------------------------
  BMD total body (g/cm^2^)                                 1.010 (0.945--1.074)   1.002 (0.943--1.067)   0.994 (0.934--1.056)   − 0.01 (− 0.01 to 0.001)                         0.30                                 0.090
  BMD femoral neck (g/cm^2^)                               0.761 (0.677--0.865)   0.748 (0.668--0.846)   0.733 (0.641--0.831)   − 0.01 (− 0.03 to − 0.003)                       0.11                                 0.016
  BMC total body (g)                                       2085 (1832--2310)      2026 (1812--2260)      1977 (1765--2210)      − 31 (− 58 to − 5)                               0.11                                 0.020
  BMC femoral neck (g)                                     3.8 (3.26--4.6)        3.8 (3.30--4.4)        3.7 (3.18--4.4)        − 0.1(− 0.2 to − 0.01)                           0.21                                 0.030
  QUS_BUA (dB/MHz)                                         101.4 (94.1--108.0)    103.0 (96.2--108.7)    100.7 (94.1--107.7)    − 0.1 (− 1.1 to 0.8)                             0.11                                 0.76
  QUS_SoS (m/s)                                            1525 (1505--1540)      1523 (1508--1541)      1516 (1501--1537)      − 3.1 (− 5.7 to − 0.4)                           0.032                                0.021
  QUS_Stiffness Index                                      71.2 (62.1--80.2)      72.0 (64.0--81.3)      69.0 (59.4--79.1)      − 0.76 (− 1.99 to 0.49)                          0.043                                0.23
  Weight (kg)                                              67 (59--75)            67 (60--75)            67 (61--76)            − 0.01 (− 1.03 to 1.01)                          0.88                                 0.98
  BMI (kg/m^2^)                                            26.1 (23.7--28.6)      25.9 (23.3--28.7)      26.0 (23.4--28.7)      − 0.03 (− 0.40 to 0.34)                          0.83                                 0.86
  Total body fat mass (kg)                                 25.57 (20.54--31.13)   25.62 (20.66--31.19)   26.47 (21.03--31.77)   173.45 (− 557.99 to 904.88)                      0.79                                 0.64
  Total body lean mass (kg)                                36.98 (34.80--40.21)   36.82 (34.59--39.74)   37.20 (34.84--39.14)   − 108.83 (− 476.28 to 258.61)                    0.86                                 0.56
                                                                                                                                                                                                                      
  PEAK-25                                                  GG                     GA                     AA                     β-Value (adj)[a](#tf0005){ref-type="table-fn"}   P[b](#tf0010){ref-type="table-fn"}   P[c](#tf0015){ref-type="table-fn"} (adj)
  BMD total body (g/cm^2^)                                 1.158 (1.115--1.222)   1.177 (1.126--1.221)   1.168 (1.128--1.229)   0.003 (− 0.003 to 0.01)                          0.12                                 0.32
  BMD femoral neck (g/cm^2^)                               1.037 (0.970--1.129)   1.045 (0.976--1.130)   1.052 (0.962--1.142)   0.001 (− 0.01 to 0.01)                           0.28                                 0.79
  BMD lumbar spine (g/cm^2^)                               1.226 (1.135--1.298)   1.234 (1.148--1.334)   1.249 (1.143--1.332)   0.01 (− 0.004 to 0.02)                           0.42                                 0.21
  BMC total body (g)                                       2534 (2343--2763)      2575 (2336--2846)      2619 (2363--2866)      8.33 (− 19.66 to 36.33)                          0.39                                 0.56
  BMC femoral neck (g)                                     4.9 (4.5--5.4)         5.0 (4.5--5.5)         5.1 (4.5--5.6)         0.02 (− 0.04 to 0.08)                            0.35                                 0.55
  BMC lumbar spine (g)                                     51.8 (46.8--57.9)      52.7 (47.24--58.5)     53.2 (46.87--59.3)     0.20 (− 0.53 to 0.94)                            0.69                                 0.59
  QUS_BUA (dB/MHz)                                         116.1 (110.5--122.0)   116.8 (110.2--123.4)   115.4 (109.1--125.6)   − 0.2 (− 1.2 to 0.8)                             0.74                                 0.70
  QUS_SoS (m/s)                                            1574 (1555--1594)      1570 (1551--1595)      1569 (1546--1598)      − 1.44 (− 4.55 to 1.67)                          0.14                                 0.36
  QUS_Stiffness Index                                      98.3 (90.1--108.6)     97.9 (88.6--108.1)     97.0 (86.6--110.1)     − 0.53 (− 1.93 to 0.88)                          0.29                                 0.46
  Trabecular bone score[d](#tf0020){ref-type="table-fn"}   1.42 (1.37--1.46)      1.43 (1.38--1.47)      1.42 (1.38--1.46)      0.001 (− 0.01 to 0.01)                           0.33                                 0.76
  Weight (kg)                                              63 (57--69)            62 (57--69)            64 (58--72)            1.09 (0.1 to 2.09)                               0.16                                 0.031
  BMI (kg/m^2^)                                            22.4 (20.7--24.5)      22.2 (20.2--24.6)      22.7 (20.8--25.0)      0.31 (− 0.02 to 0.64)                            0.09                                 0.07
  Total body fat mass (kg)                                 19.54 (15.39--24.47)   19.03 (14.99--24.52)   20.40 (15.78--26.89)   837.80 (102.76 to 1572.85)                       0.09                                 0.026
  Total body lean mass (kg)                                39.86 (37.42--42.86)   40.22 (37.08--43.27)   40.57 (37.42--43.74)   192.58 (− 224.09 to 609.25)                      0.64                                 0.37

BMD (bone mineral density), BMC (bone mineral content), QUS (quantitative ultrasound; SoS (speed of sound), BUA (broadband ultrasound attenuation), SI (stiffness index). Values are median (interquartile range).

(GG vs. GA vs. AA).

Kruskal-Wallis.

Linear regression --- adjusted for fat mass.

Additionally adjusted for fat mass & LS BMD.

###### 

Association between *GIPR* (rs10423928) and bone composition.

  OPRA                                                     TT                     TA                     AA                     β-Value (adj)[a](#tf0025){ref-type="table-fn"}   p[b](#tf0030){ref-type="table-fn"}   p[c](#tf0035){ref-type="table-fn"} (adj)
  -------------------------------------------------------- ---------------------- ---------------------- ---------------------- ------------------------------------------------ ------------------------------------ ------------------------------------------
  BMD total body (g/cm^2^)                                 0.999 (0.943--1.073)   1.002 (0.934--1.064)   1.021 (0.967--1.060)   0.003 (− 0.01 to 0.01)                           0.56                                 0.49
  BMD Femoral neck (g/cm^2^)                               0.758 (0.666--0.851)   0.739 (0.655--0.835)   0.763 (0.706--0.867)   − 0.003 (− 0.02 to 0.01)                         0.44                                 0.70
  BMC total body (g)                                       2046 (1798--2285)      2023 (1810--2230)      2191 (1899--2290)      12 (− 20 to 45)                                  0.26                                 0.45
  BMC femoral neck (g)                                     3.8(3.3--4.5)          3.7 (3.2--4.4)         3.9 (3.5--4.5)         − 0.03 (− 0.12 to 0.07)                          0.21                                 0.58
  QUS_BUA (dB/MHz)                                         101.4 (96.0--108.0)    102.5 (96.0--108.0)    103.0 (95.6--110.4)    0.77 (− 0.35 to 1.88)                            0.62                                 0.18
  QUS_SoS (m/s)                                            1521 (1504--1538)      1523 (1506--1541)      1528 (1509--1545)      2.45 (− 0.73 to 5.64)                            0.38                                 0.13
  QUS_Stiffness Index                                      70.1 (62.1--79.1)      72.3 (63.0--81.0)      72.2 (63.8--85.4)      1.26 (− 0.23 to 2.74)                            0.45                                 0.10
                                                                                                                                                                                                                      
  PEAK-25                                                  TT                     TA                     AA                     β-Value (adj)[a](#tf0025){ref-type="table-fn"}   p[b](#tf0030){ref-type="table-fn"}   p[c](#tf0035){ref-type="table-fn"} (adj)
  BMD total body (g/cm^2^)                                 1.166 (1.124--1.221)   1.177 (1.122--1.225)   1.152 (1.115--1.217)   0.002 (− 0.01 to 0.01)                           0.38                                 0.57
  BMD femoral neck (g/cm^2^)                               1.040 (0.972--1.130)   1.048 (0.961--1.132)   1.049 (0.960--1.131)   0.001 (− 0.01 to 0.01)                           0.97                                 0.83
  BMD lumbar spine (g/cm^2^)                               1.232 (1.139--1.322)   1.237 (1.153--1.321)   1.256 (1.164--1.335)   0.01 (− 0.01 to 0.02)                            0.84                                 0.20
  BMC total body (g)                                       2562 (2343--2828)      2584 (2345--2841)      2506 (2348--2763)      9.72 (− 22.31 to 41.75)                          0.82                                 0.55
  BMC Femoral neck (g)                                     5.0 (4.6--5.5)         5.0 (4.5--5.6)         5.1 (4.6--5.5)         0.03 (− 0.04 to 0.10)                            0.97                                 0.34
  BMC lumbar spine (g)                                     52.8 (47.2--58.5)      52.2 (46.9--59.2)      51.7 (46.1--57.5)      0.2 (− 0.64 to 1.04)                             0.78                                 0.64
  QUS_BUA (dB/MHz)                                         117.1 (110.4--124.7)   114.6 (109.1--121.5)   115.4 (108.8--121.7)   − 1.63 (− 2.79 to − 0.47)                        0.011                                0.006
  QUS_SoS (m/s)                                            1572 (1552--1597)      1568 (1549--1593)      1567 (1546--1586)      − 2.77 (− 6.40 to 0.87)                          0.10                                 0.14
  QUS_Stiffness Index                                      97.8 (88.9--109.7)     96.4 (86.8--107.0)     94.5 (87.3--103.9)     − 1.86 (− 3.49 to − 0.22)                        0.03                                 0.026
  Trabecular bone score[d](#tf0040){ref-type="table-fn"}   1.43 (1.38--1.47)      1.42 (1.38--1.46)      1.44 (1.38--1.48)      0.001 (− 0.01 to 0.01)                           0.62                                 0.84

BMD (bone mineral density), BMC (bone mineral content), QUS (quantitative ultrasound; SoS (speed of sound), BUA (broadband ultrasound attenuation), SI (stiffness index). Reported values are median (interquartile range).

(TT vs. TA vs. AA).

Kruskal-Wallis.

Adjusted for fat mass (linear regression).

Additionally adjusted for fat mass & LS BMD.

###### 

Association of GIP and GIPR polymorphisms with incident fracture[a](#tf0045){ref-type="table-fn"} in OPRA women.

                    TT            TA            AA            p             
  ----------------- ------------- ------------- ------------- ------------- -------
  rs10423928_GIPR   Fracture      312 (62.5%)   165 (33.1%)   22 (4.4%)     0.838
  No fracture       298 (60.7%)   170 (34.6%)   23 (4.7%)                   
                                                                            
                    GG            GA            AA            p             
  rs2291725_GIP     Fracture      134 (26.9%)   242 (48.6%)   122 (24.5%)   0.450
  No fracture       137 (27.8%)   251 (51.0%)   104 (21.1%)                 

p-Value calculated by the χ^2^ test.

Incident fracture of any type (includes hip, distal radius, vertebra, shoulder, pelvis and proximal tibia fractures).

[^1]: These authors contributed equally.
